BACKGROUND: The aim of this study is to report the perioperative outcomes of CRS 
and HIPEC from a single institution and review those factors that are associated 
with a poor perioperative outcome in patients with peritoneal dissemination from 
primary or recurrent ovarian cancer.
PATIENTS AND METHOD: A retrospective cohort study setting was conducted in a 
third level hospital peritoneal surface malignancy program. Ninety one patients 
diagnosed with ovarian peritoneal carcinomatosis, primary and recurrent without 
extraperitoneal metastasis were included for cytoreductive surgery and HIPEC 
with paclitaxel. We analyzed the postoperative morbidity rates and a univariate 
and multivariate analysis of factors associated with overall (grade I-IV) and 
major (grade III-IV) postoperative morbidity were performed.
RESULTS: Peritoneal Cancer Index (PCI) upper than 12 (OR = 2.942 95%: 
1.892-9.594 p = 0.044) was an independent factor associated with the occurrence 
of I-IV postoperative morbidity. Regarding major complications (grade III-IV), 
on multivariate analysis, in addition to PCI >12 (OR = 6.692, 95% CI: 1974-45, 
674, p = 0.032), the need to carry out intestinal resection (OR = 4.987, 95% CI: 
1350-27, 620, p = 0.046) was an independent factor related with major morbidity 
(grade III-IV).
CONCLUSIONS: The use of HIPEC after aggressive cytoreductive surgery in patients 
with ovarian cancer with peritoneal dissemination can be performed with 
acceptable postoperative morbidity rates. Knowledge of the factors associated 
with the onset of these postoperative adverse events allows better management of 
the same and offers the patient a safe procedure.